Search results: (10000)
News New Antidiabetic Drugs in Cardiovascular Prevention in International Recommendations
Results from studies on new antidiabetic drugs showing cardiovascular (CV) benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i, gliflozins) and glucagon-like peptide 1 receptor agonists (GLP-1RA) have led to efforts to create new recommendations for their use in patients with type 2 diabetes mellitus (T2DM) for primary and secondary CV disease prevention. A recent review by American experts succinctly summarizes what current guidelines from American and European professional societies say on this subject.
News Cardiovascular Interventions with Continued Therapy with Dabigatran − Insights from the GLORIA-AF Study
An analysis using data from an international registry of patients with newly diagnosed atrial fibrillation evaluated the safety and efficacy of continued therapy with dabigatran during cardioversion or atrial fibrillation ablation, pacemaker implantation, and coronary angiography with possible stent implantation.
News Fresh data from real clinical practice on targeted treatment of RA with etanercept: Should therapy be changed after 12 weeks due to insufficient response?
A recently published German study investigated, among other things, what percentage of patients with rheumatoid arthritis (RA) achieve remission or low disease activity after a certain period of etanercept treatment in real clinical practice.
News Study COPDGene Redefines Diagnostic Criteria of Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease ranks among the top causes of morbidity and mortality worldwide. Current diagnostic criteria for the disease are based exclusively on spirometric examination. Increasing evidence, however, suggests that a significant number of patients show signs of chronic obstructive pulmonary disease without pathological findings on spirometry. The analysis of the COPDGene study thus proposes expanding the diagnostic criteria to include additional parameters.
News Brigatinib in the Therapy of ALK-Positive NSCLC – First Results of the J-ALTA Study
Brigatinib is an anaplastic lymphoma kinase (ALK) inhibitor with broad and potent activity against ALK gene mutations causing resistance to ALK inhibitor therapy (ALKi). In patients refractory to crizotinib therapy, brigatinib administration in phase III clinical trials led to high systemic and intracranial therapeutic responses and concurrently improved median progression-free survival (PFS). The primary analysis objective of the phase II J-ALTA clinical study, presented at this year's American Society of Clinical Oncology (ASCO) congress, was to assess the efficacy and safety of therapy in patients with ALK-positive NSCLC naïve to previous ALKi therapy.
News Non-factor vs. Factor Prophylaxis of Hemophilia A: A Comparison of Cost and Treatment Effectiveness Based on Real-World Data from the USA
In the prophylactic treatment of patients with hemophilia A, particularly its severe form, concentrates of clotting factor VIII (FVIII) with extended half-life (EHL) are increasingly administered, or non-factor treatment, represented in clinical practice by FVIII mimetic antibody emicizumab. However, insights into the direct comparison of effectiveness and economic burden arising from prophylaxis with these modalities are limited, including data from real-world practice. One recently published study therefore attempted to conduct such a retrospective comparison based on data from healthcare-related databases in the USA.
News Efficacy and Safety of Dual Bronchodilator Therapy for COPD – From Randomized Clinical Trials to Real-World Clinical Practice
Dual bronchodilator therapy (LAMA + LABA) represents one of the mainstays of treating chronic obstructive pulmonary disease (COPD). The aim of the recent systematic review presented below was to assess the efficacy and safety of this dual therapy compared to monotherapy or other combinations in the context of clinical trials and real-world clinical practice.
News Changes in Blood Count as Possible Prognostic Markers of Response to Panitumumab in Patients with mCRC
As part of the VALENTINO study with panitumumab in patients with metastatic colorectal cancer without RAS mutation, the connection between certain blood count parameters associated with inflammation and patient prognosis was investigated.
News Cannabidiol as a way to reduce anxiety in patients with Parkinson's disease?
A recent study by Brazilian authors examined the effects of cannabidiol on tremors and anxiety in patients with Parkinson's disease. Could it represent a promising modality in this indication?
News Sports in People with Hemophilia – Possible and Safe
Active involvement in sports and an active lifestyle are important aspects of daily functioning for people with hemophilia. Modern treatment of this disease, including the prophylactic administration of concentrates of the missing coagulation factor, has led to an increase in the number of very active patients. Numerous studies have confirmed that they are as physically active as the general population, although some emphasize that this is more relevant to children and young people. Therefore, the work of Dutch and Swedish authors focused on examining the relationship between age and physical activity in hemophiliacs, especially with regard to more intensive and riskier sports.
News Use of Inclisiran in a Patient in Secondary Cardiovascular Prevention
Lowering LDL cholesterol (LDL-c) is one of the primary goals for reducing cardiovascular (CV) risk due to its proven mortality reduction. However, many patients with familial hypercholesterolemia or CV disease fail to reach target LDL-c levels even when given the maximum tolerated dose of conventional hypolipidemic treatment. For these patients, inclisiran—a small interfering RNA (siRNA) that lowers cholesterol—offers hope. In the following article, we present a model example of a patient after an acute coronary event for whom starting inclisiran treatment is appropriate.
News Do Beta-Blockers Increase the Risk of Hypoglycemia in Patients with Diabetes and Atherosclerosis?
Given that a large portion of patients with diabetes have proven cardiovascular disease, several clinical studies or their subsequent analyses address the effects of beta-blockers in these patients. One such analysis was the post-hoc analysis of the TECOS study, which among other things, attempted to evaluate the connection between the use of beta-blockers in type 2 diabetics with proven atherosclerotic cardiovascular disease and the incidence of hypoglycemic episodes.
News Turoctocog Alfa in Tertiary Prophylaxis of Hemophilia A or Is It Always About Bleeding? Case Studies
This case report from our own practice concerns our experience with the treatment of hemophilia A with turoctocog alfa. The intention is, among other things, to compare different outcomes in our two patients regarding their self-assessment of bleeding without objective validation.
News Brief from ASH 2021: News and Advances in CLL Treatment
The summary from the first day of the 63rd American Society of Hematology (ASH) Congress in Atlanta in December 2021 brought several new advancements in the treatment of chronic lymphocytic leukemia (CLL). Dr. Brian Koffman from the CLL Society provided commentary on these developments.
News Ixekizumab administered for 5 years demonstrated high efficacy and a favorable safety profile in patients with moderate to severe psoriasis
Ixekizumab is a recombinant humanized monoclonal antibody against interleukin 17A, indicated for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis. At the 24th World Congress of Dermatology in Milan in June 2019, results were presented from a study evaluating the efficacy and safety of long-term administration of ixekizumab.
News Effectiveness of Dietary Intervention in Irritable Bowel Syndrome – Results of a Network Meta-Analysis
A low FODMAP diet is often recommended to alleviate symptoms of irritable bowel syndrome (IBS). Although several randomized studies have been conducted to assess the effectiveness of this diet, a systematic evaluation has yet to be available, and individual studies have used various control interventions. Therefore, an international team of researchers decided to prepare a systematic literature review with a network analysis, recently published in the journal Gut.
News Safety of Riociguat in the Treatment of Thromboembolic Pulmonary Hypertension in Common Practice
In March 2021, the final safety results of riociguat in the treatment of thromboembolic pulmonary arterial hypertension in real-world practice were published from the international EXPERT registry, which also included Czech patients. The safety profile of the therapy was consistent with the findings of previous clinical studies.
News Pain Relief and Functional Score Improvement in Patients with Low Rheumatoid Arthritis Activity: Baricitinib vs. Adalimumab
In patients with rheumatoid arthritis, pain and functional impairment may persist even with good disease activity control. An exploratory analysis of the RA-BEAM study compared the effects of baricitinib, adalimumab, and placebo added to methotrexate on residual pain and functional scores in patients with rheumatoid arthritis (RA) who achieved remission or low disease activity with this treatment.
News Efficacy of Combination Therapy for Chronic Lymphocytic Leukemia in Patients with Complex Karyotype
A complex karyotype (presence of ≥ 3 chromosomal abnormalities) is a negative prognostic marker in chronic lymphocytic leukemia (CLL). An analysis of the impact of complex karyotype on the efficacy of targeted CLL therapy combining the monoclonal antibody against CD20 antigen obinutuzumab with the BCL2 inhibitor venetoclax or the alkylating cytostatic chlorambucil was published in the journal Blood.
News Alzheimer's Disease – Another Pandemic on the Horizon?
Due to the COVID-19 pandemic, other current problems often get pushed into the background. One of these is the aging population and the increasing prevalence of dementia. The key question thus becomes how to extend the period of active aging as much as possible.